ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

March 9, 2018: By Joan McKenna

ViewPoint Therapeutics announced March 5 that it raised $35 million in a Series B financing.

The biotech company is developing crystallin stabilizers to treat and prevent cataracts and presbyopia using a topical treatment.

ViewPoint said it plans to use the proceeds to advance its lead product candidate, VP1-001, through clinical proof-of-concept studies.

The company says crystallins (alpha-, beta-, and gamma-) are the fibrous proteins that form the majority of the structure of the eye’s natural lens. In their native, properly-folded state, crystallins give the lens its transparency, refractive index, and flexibility.

ViewPoint says it has identified a molecule that effectively stabilizes the soluble native form of alpha-crystallin to reduce misfolding and aggregation, and consequently prevent and counteract lens disorders such as cataracts and presbyopia.

ViewPoint was founded in July 2014 based on technology developed in the lab of Jason Gestwicki at the University of Michigan, in collaboration with the lab of Usha Andley at Washington University in St. Louis. ViewPoint’s operations are based in Janssen Labs in San Francisco.

The financing was led by The Rise Fund with participation from Novo Holdings A/S and other investors. The Rise Fund was co-founded by TPG Growth founder Bill McGlashan, U2 lead singer Bono, and entrepreneur Jeff Skoll.


Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023